Recursion Pharmaceuticals (RXRX) Accumulated Depreciation & Amortization (2022 - 2024)
Historic Accumulated Depreciation & Amortization for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q4 2024 value amounting to $36.5 million.
- Recursion Pharmaceuticals' Accumulated Depreciation & Amortization rose 4955.33% to $36.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $36.5 million, marking a year-over-year increase of 4955.33%. This contributed to the annual value of $36.5 million for FY2024, which is 4955.33% up from last year.
- According to the latest figures from Q4 2024, Recursion Pharmaceuticals' Accumulated Depreciation & Amortization is $36.5 million, which was up 4955.33% from $23.5 million recorded in Q3 2024.
- Recursion Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $36.5 million for Q4 2024, and its period low was $2.8 million during Q1 2022.
- Its 3-year average for Accumulated Depreciation & Amortization is $15.3 million, with a median of $14.1 million in 2022.
- Over the last 5 years, Recursion Pharmaceuticals' Accumulated Depreciation & Amortization had its largest YoY gain of 10757.06% in 2023, and its largest YoY loss of 3473.08% in 2023.
- Quarter analysis of 3 years shows Recursion Pharmaceuticals' Accumulated Depreciation & Amortization stood at $11.8 million in 2022, then soared by 107.57% to $24.4 million in 2023, then surged by 49.55% to $36.5 million in 2024.
- Its Accumulated Depreciation & Amortization was $36.5 million in Q4 2024, compared to $23.5 million in Q3 2024 and $16.3 million in Q2 2024.